NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis $17.95 +0.83 (+4.85%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$17.40▼$18.2850-Day Range$12.53▼$17.9552-Week Range$9.18▼$48.31Volume172,349 shsAverage Volume338,810 shsMarket Capitalization$460.42 millionP/E RatioN/ADividend YieldN/APrice Target$61.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tourmaline Bio alerts: Email Address Tourmaline Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside244.3% Upside$61.80 Price TargetShort InterestBearish13.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.94) to ($3.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector624th out of 936 stocksBiological Products, Except Diagnostic Industry102nd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingTourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTourmaline Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tourmaline Bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.64% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Tourmaline Bio has recently increased by 36.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRML. Previous Next 3.8 News and Social Media Coverage News SentimentTourmaline Bio has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tourmaline Bio this week, compared to 2 articles on an average week.Search Interest5 people have searched for TRML on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows1 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have not sold or bought any company stock.Percentage Held by Insiders11.02% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tourmaline Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($2.94) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tourmaline Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Tourmaline Bio Stock (NASDAQ:TRML)Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Read More TRML Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRML Stock News HeadlinesJune 27, 2024 | globenewswire.comTourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial OfficerMay 23, 2024 | globenewswire.comTourmaline Bio to Present at the Jefferies Global Healthcare ConferenceJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tourmaline Bio Amid Progress in TOUR006 Trials and Expansion OpportunitiesMay 16, 2024 | globenewswire.comTourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY TrialMay 14, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)May 13, 2024 | investorplace.comTRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024May 13, 2024 | globenewswire.comTourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 22, 2024 | seekingalpha.comTourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly BearishMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tourmaline Bio Amidst Promising Clinical Trials and Drug Candidate ProspectsMarch 19, 2024 | investorplace.comTRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023March 19, 2024 | globenewswire.comTourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 16, 2024 | ca.finance.yahoo.comTRML Apr 2024 55.000 callMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 20.000 putMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 35.000 putMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 50.000 callMarch 13, 2024 | markets.businessinsider.comTruist Financial Gives a Buy Rating to Tourmaline Bio (TRML)See More Headlines Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CUSIPN/A CIK1827506 WebN/A Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$61.80 High Stock Price Target$74.00 Low Stock Price Target$48.00 Potential Upside/Downside+244.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.56% Return on Assets-18.91% Debt Debt-to-Equity RatioN/A Current Ratio62.17 Quick Ratio62.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book1.78Miscellaneous Outstanding Shares25,650,000Free Float22,821,000Market Cap$460.42 million OptionableOptionable Beta2.30 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Sandeep C. Kulkarni M.D. (Age 42)Co-Founder, CEO & Director Comp: $753.02kDr. Yung H. Chyung M.D. (Age 47)Chief Medical Officer Comp: $624.63kDr. Kevin B. Johnson M.B.A. (Age 60)Ph.D., Chief Regulatory Officer Comp: $555.84kMr. Ryan Robinson CPA (Age 36)VP of Finance, Controller & Interim CFO Dr. Susan Dana Jones Ph.D. (Age 64)Chief Technology Officer Mr. W. Bradford Middlekauff J.D. (Age 62)Chief Business Officer, General Counsel & Corporate Secretary Ms. Kimberly PiorkowskiVice President of People, Culture and ComplianceMr. Ryan IarrobinoSVP of Product DevelopmentMs. Dora RauSenior Vice President & Head of QualityMr. Gerhard Hagn Pharm.D.Senior VP and Head of Commercial & Business DevelopmentMore ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXVir BiotechnologyNASDAQ:VIRSana BiotechnologyNASDAQ:SANARelay TherapeuticsNASDAQ:RLAYAutolus TherapeuticsNASDAQ:AUTLView All CompetitorsInsiders & InstitutionsAlphaCentric Advisors LLCBought 13,900 shares on 7/26/2024Ownership: 0.292%Bank of New York Mellon CorpBought 70,697 shares on 7/26/2024Ownership: 0.276%SG Americas Securities LLCBought 33,666 shares on 7/12/2024Ownership: 0.131%Artal Group S.A.Bought 223,070 shares on 5/17/2024Ownership: 1.226%Janus Henderson Group PLCBought 11,593 shares on 5/16/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions TRML Stock Analysis - Frequently Asked Questions How have TRML shares performed this year? Tourmaline Bio's stock was trading at $26.18 at the beginning of 2024. Since then, TRML stock has decreased by 31.4% and is now trading at $17.95. View the best growth stocks for 2024 here. How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.13. Who are Tourmaline Bio's major shareholders? Tourmaline Bio's top institutional shareholders include AlphaCentric Advisors LLC (0.29%), Bank of New York Mellon Corp (0.28%) and SG Americas Securities LLC (0.13%). Insiders that own company stock include Sandeep Chidambar Kulkarni, Mark Mcdade and Parvinder Thiara. View institutional ownership trends. How do I buy shares of Tourmaline Bio? Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRML) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
